中信证券股份有限公司 关于苏州纳微科技股份有限公司 使用部分暂时闲置募集资金进行现金管理的核查意见 中信证券股份有限公司（以下简称"中信证券"、"保荐机构"）为苏州纳微科 技股份有限公司（以下简称"公司"、"纳微科技"）首次公开发行股票并上市持续 督导期间的保荐机构。根据《中华人民共和国公司法》《中华人民共和国证券法》 《证券发行上市保荐业务管理办法（2023 年修订）》《上海证券交易所科创板股 票上市规则（2023 年 8 月修订）》《上海证券交易所科创板上市公司自律监管指 引第 1 号——规范运作（2023 年 8 月修订）》《科创板上市公司持续监管办法（试 行）》及《上市公司监管指引第 2 号——上市公司募集资金管理和使用的监管要 求（2022 年修订）》等有关规定，对纳微科技使用部分首次公开发行股票暂时闲 置募集资金进行现金管理事项进行了核查，核查情况及核查意见如下： 一、募集资金基本情况 根据中国证券监督管理委员会于 2021 年 4 月 21 日出具的《关于同意苏州纳 微科技股份有限公司首次公开发行股票注册的批复》（证监许可〔2021〕1395 号）， 公司首次向社会公开发行人民币普通股（A）股 ...

RSM 容诚 前次募集资金使用情况鉴证报告 苏州纳微科技股份有限公司 容诚专字[2023]200Z0651号 容诚会计师事务所(特殊普通合伙) 中国.北京 些码用于证明该市计报告是否由具有执业许可的会计师事务所出县， "注册会计师行业统一监管平台 (http://acc.m ofsov.cn)"进行喜指 报 告编列：京239Y9NZJ00 您可使用手机"扫一扫" 或进入 诚 . RSM 容 诚 容 诚会计师事务所(特殊普通合伙) 总所：北 京市西域区阜成门外大街22号 外经贸大厦15层 /922-926(100037 ) TEL:010- 6600 1391 FAX:010-6600 1392 E-mall bjārsmch nacomcn https //wwwrsmglobal/chlna/ 前次募集资金使用情况鉴证报告 容诚专字[2023]200Z0651号 苏州纳微科技股份有限公司全体股东： 目 录 | 序号 | r | 容 | 项码 | | --- | --- | --- | --- | | l | 前次募集资金使用情况鉴证报告 | | 1-3 | | 2 | 前次募集资金使用情况专项报告 | | ...

证券代码：688690 证券简称：纳微科技 公告编号：2023-049 苏州纳微科技股份有限公司 第二届董事会第二十五次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、董事会会议召开情况 苏州纳微科技股份有限公司（以下简称"公司"）第二届董事会第二十五次 会议于 2023 年 8 月 24 日 9:00 以线上线下相结合的方式召开。本次会议由董事 长江必旺博士主持，会议应到董事 9 名，实到董事 9 名，符合《中华人民共和国 公司法》和《苏州纳微科技股份有限公司章程》的有关规定，会议决议合法、有 效。 二、董事会会议审议情况 （一）审议通过《关于公司<2023 年半年度报告>及摘要的议案》 经审议，董事会确认公司 2023 年半年度报告的编制和审议程序符合法律、 法规、《公司章程》和公司内部管理制度的各项规定；公司 2023 年半年度报告的 内容与格式符合中国证券监督管理委员会和上海证券交易所的各项规定，所包含 的信息能从各方面客观、真实、公允地反映出公司 2023 年半年度的经营管理和 财务状况等事项； ...

证券代码：688690 证券简称：纳微科技 公告编号：2023-044 苏州纳微科技股份有限公司 2023 年半年度募集资金存放与实际使用情况的 专项报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 根据中国证券监督管理委员会（以下简称"证监会"）《上市公司监管指引第 2号——上市公司募集资金管理和使用的监管要求》（证监会公告[2012]44号）、 《上海证券交易所科创板上市公司自律监管规则适用指引第1号——规范运作》、《上海 证券交易所上市公司募集资金管理办法（2013年修订）》（上证公字[2013]13号） 的规定，公司编制了截至2023年6月30日的《募集资金存放与实际使用情况专项报 告》。 一、募集资金基本情况 （一）募集资金情况说明 （1）A股首次公开发行募集资金情况 （2）2022年A股向特定对象发行募集资金情况 有限公司、财通基金管理有限公司、国泰君安证券股份有限公司、JPMorgan Chase Bank, National Association、国信证券股份有限公司、深圳市恒泰融安投资管 理有限公司 ...

证券代码：688690 证券简称：纳微科技 公告编号：2023-050 苏州纳微科技股份有限公司 第二届监事会第二十一次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、监事会会议召开情况 苏州纳微科技股份有限公司（以下简称"公司"）第二届监事会第二十一次 会议于 2023 年 8 月 24 日以线上线下相结合的方式召开。会议应出席监事 3 名， 实际出席 3 名，符合《中华人民共和国公司法》和《苏州纳微科技股份有限公司 章程》的有关规定，会议决议合法、有效。 二、监事会会议审议情况 （一）审议通过《关于公司<2023 年半年度报告>及摘要的议案》 经审议，监事会确认公司 2023 年半年度报告的编制和审议程序符合法律、 法规、《公司章程》和公司内部管理制度的各项规定；公司 2023 年半年度报告的 内容与格式符合中国证券监督管理委员会和上海证券交易所的各项规定，所包含 的信息能从各方面客观、真实、公允地反映出公司 2023 年半年度的经营管理和 财务状况等事项；监事会成员能够保证公司 2023 年半年度报 ...

苏州纳微科技股份有限公司第二届董事会 第二十五次会议独立董事独立意见 根据《中华人民共和国公司法》《上海证券交易所科创板股票上市规则》《关 于在上市公司建立独立董事制度的指导意见》等法律法规和规范性文件以及《苏 州纳微科技股份有限公司章程》的相关规定，作为苏州纳微科技股份有限公司 （以下简称"公司"）的独立董事，本着认真、负责的态度，基于独立、审慎、 客观的原则，我们认真审阅了本次会议的相关资料，现针对公司第二届董事会第 二十五次会议相关议案发表明确同意的独立意见如下： 一、关于公司 2023 年半年度募集资金存放与实际使用情况的专项报告的议 案 公司编制的 2023 年半年度募集资金存放与实际使用情况的专项报告，募集 资金的审批程序符合《上市公司监管指引第 2 号——上市公司募集资金管理和使 用的监管要求》、《上海证券交易所上市公司募集资金管理办法》等相关法律法 规的要求，不存在变相改变募集资金投向和损害中小股东利益的情形。 公司延长向不特定对象发行可转换公司债券股东大会决议有效期事项，符合 相关法律法规及规范性文件的规定，符合公司和全体股东利益，不存在损害中小 股东利益的情形。因此，我们同意公司延长向不特 ...

证券代码：688690 证券简称：纳微科技 公告编号：2023-047 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、关联交易概述 公司拟与参股公司鑫导电子签署《资产转让协议》。根据厦门嘉学资产评估 房地产估价有限公司（以下简称"嘉学评估"）出具的《苏州纳微科技股份有限 公司拟资产转让涉及的ACF用导电微球相关专利权及设备资产评估报告》（嘉学 评估评报字【2023】8310066号），公司ACF用导电微球相关专利权及设备在评估 基准日2023年6月30日采用成本法评估的评估值为人民币2,843.48万元（不含增 值税），参考上述评估值，双方协商一致确认，转让价格为以下三者合计： 苏州纳微科技股份有限公司 关于签署资产转让协议暨关联交易的公告 1、有形资产转让费：人民币 150 万元（不含增值税）； 2、专利转让费之固定部分：人民币 2,850 万元（不含增值税）； 3、专利转让费之提成部分：鑫导电子按应用本协议无形资产所开发或转化 的各向异性导电胶膜产品的销售总收入的3%向公司支付，于每年度第一季度末 ...

证券代码：688690 证券简称：纳微科技 公告编号：2023-045 苏州纳微科技股份有限公司 关于延长公司向不特定对象发行可转换公司债券股东 大会决议有效期及授权有效期的公告 二、独立董事的独立意见 公司延长向不特定对象发行可转换公司债券股东大会决议有效期及授权有效 期事项，符合相关法律法规及规范性文件的规定，符合公司和全体股东利益，不 存在损害中小股东利益的情形。因此，我们同意公司延长向不特定对象发行可转 换公司债券股东大会决议有效期及授权有效期的事项。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、基本情况说明 （或由董事会授权人士）的有效期均为公司2022年第三次临时股东大会审议通过 之日起12个月，即2022年9月14日至2023年9月13日。 鉴于公司本次发行方案的股东大会决议有效期及授权有效期即将届满而公司 尚未完成本次发行工作，为确保公司本次发行后续工作持续、有效、顺利进行。 公司于2023年8月24日召开第二届董事会第二十五次会议及第二届监事会第二十 一次会议，审议通过《关于延长公司向不特定对象发 ...

Financial Performance - The company's operating revenue for the reporting period was 705.84 million RMB, with a net profit of 276.86 million RMB, indicating a relatively small scale compared to large multinational companies, which poses a risk to operational resilience [1]. - The company achieved a revenue of 705.84 million RMB, representing a year-on-year growth of 58.14% [20]. - Net profit attributable to shareholders was 275.13 million RMB, a year-on-year increase of 46.27% [20]. - The net profit after deducting non-recurring gains and losses was 197.05 million RMB, up 14.46% compared to the previous year [20]. - In the biopharmaceutical sector, revenue reached 590.30 million RMB, with a growth rate of 51.27% [22]. - The company reported a revenue increase of 15% year-over-year, reaching RMB 1.2 billion in the latest quarter [124]. - The company provided a forward guidance of 10% revenue growth for the next quarter, projecting revenues between RMB 1.3 billion and RMB 1.4 billion [124]. - The company reported a total of RMB 1,588.53 million in other current liabilities, primarily due to endorsed or discounted receivables not yet due [63]. - The company's operating revenue for 2022 was RMB 70,584.12 million, representing a 58.14% increase compared to RMB 44,634.68 million in 2021 [190]. - The net profit attributable to shareholders for 2022 was RMB 27,512.76 million, a growth of 46.27% from RMB 18,808.97 million in 2021 [190]. Accounts Receivable and Cash Flow - Accounts receivable at the end of the reporting period amounted to 230.79 million RMB, accounting for 32.70% of the current operating revenue, indicating potential risks related to credit losses [4]. - The net cash flow from operating activities decreased by 28.99% to 111.89 million RMB compared to the previous year [46]. - The cash flow from operating activities decreased year-on-year, primarily due to increased salaries and safety stock expenditures [21]. - The cash and cash equivalents decreased by 33.38% to 250.76 million RMB, reflecting a focus on managing idle funds [55]. - The net cash flow from operating activities decreased by 28.99% to RMB 11,188.81 million, down from RMB 15,756.39 million in the previous year [191]. Research and Development - The company plans to enhance its R&D and industrialization capabilities to meet higher product technical requirements and maintain its leading position in high-performance chromatography media [1]. - The company expanded its R&D team, leading to increased R&D expenses due to higher personnel costs and material consumption [21]. - R&D expenses rose by 77.12% year-on-year, totaling 117.07 million RMB, indicating a strong focus on innovation [32]. - The proportion of R&D investment to operating revenue increased to 16.59% in 2022, up from 14.81% in 2021 [190]. - The company invested $200 million in R&D for new technologies, which is a 20% increase compared to the previous year [200]. Market Expansion and Competition - The company is closely monitoring changes in biopharmaceutical industry policies to mitigate potential adverse impacts on its operations [9]. - The company faces risks related to intensified market competition as large multinational companies focus more on the Chinese market [1]. - The company plans to continue leveraging domestic market opportunities in biopharmaceuticals amid increasing demand for local suppliers [19]. - The company is actively seeking key technology targets in the upstream and downstream of the industry chain to strengthen its research and development capabilities [92]. - The competitive landscape in the Chinese biopharmaceutical market is intensifying, with increased attention from multinational companies and easier access to equity financing for domestic firms [82]. Strategic Investments and Acquisitions - The company plans to expand its market presence and enhance product offerings through strategic acquisitions and R&D investments [36]. - The company completed a strategic acquisition of a competitor for RMB 500 million, expected to enhance market competitiveness [124]. - The company is planning to issue convertible bonds to unspecified targets, with a feasibility analysis report approved in August 2022 [142]. - The company has been actively involved in capacity construction projects for its subsidiary Zhejiang Nawei Biotechnology Co., Ltd. [142]. - The company plans to construct a new R&D center with an increased investment of RMB 210 million, expanding the building area to 29,400 square meters [72]. Governance and Management - The company has established a governance structure that complies with regulatory requirements, ensuring independent operation and effective decision-making processes [98]. - The management team includes experienced professionals with backgrounds in various sectors, enhancing the company's strategic capabilities [117]. - The company has maintained a stable leadership structure with no significant changes in board members during the reporting period [121]. - The total remuneration paid to all directors, supervisors, and senior management personnel at the end of the reporting period was 1,120.60 million RMB [129]. - The company has not engaged in any significant adverse competition from controlling shareholders or actual controllers [109]. Product Development and Innovation - The company plans to develop new products, including high-capacity alkaline affinity fillers and new generation ion exchange products, to meet the rapidly evolving market demands [94]. - The company is committed to ongoing research and development efforts to drive innovation in its product offerings [117]. - New product launches contributed to a 30% increase in sales, with the latest product line accounting for RMB 300 million in revenue [124]. - The company is exploring strategic partnerships and potential acquisitions to enhance its market position [117]. - The company is focusing on technological innovation and product iteration to capitalize on the historical opportunities presented by the rapid development of the biopharmaceutical sector in China [83].

Financial Performance - The company's operating revenue for Q1 2023 was CNY 13,211.39 million, a decrease of 6.21% compared to the same period last year[4]. - Net profit attributable to shareholders was CNY 1,235.84 million, down 79.71% year-on-year[4]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 598.64 million, a decrease of 89.35% year-on-year[4]. - Basic earnings per share were CNY 0.0307, down 79.84% year-on-year[4]. - Total revenue for Q1 2023 was CNY 132,113,888.95, a decrease of 6.0% compared to CNY 140,865,673.22 in Q1 2022[48]. - Net profit for Q1 2023 was CNY 8,844,695.02, down from CNY 61,838,295.13 in Q1 2022, representing a decline of 85.7%[40]. - Adjusted net profit margin decreased to 34.29%, down 8.98 percentage points from the previous year[33]. - The company reported a total comprehensive income of CNY 8,676,508.73 for Q1 2023, significantly lower than CNY 61,781,840.32 in Q1 2022[41]. - The company recorded a net profit of CNY 13,610,162.34, a significant decrease from CNY 70,319,504.08 in the previous period[49]. Cash Flow and Assets - The net cash flow from operating activities was a negative CNY 2,477.53 million, primarily due to significant tax payments and employee performance bonuses in Q1[9]. - Cash inflow from operating activities in Q1 2023 was CNY 163,256,853.71, an increase from CNY 106,440,903.89 in Q1 2022[42]. - Total assets increased to CNY 2,026,598,984.12 in Q1 2023 from CNY 1,952,900,334.44 in Q1 2022, marking a growth of 3.8%[40]. - Cash and cash equivalents at the end of the period totaled CNY 377,117,428.47, up from CNY 212,473,150.26[53]. - The company’s cash and cash equivalents decreased to CNY 10,993,679.20 in Q1 2023 from CNY 14,428,250.40 in Q1 2022, a decline of 23.8%[40]. - The total liabilities decreased to CNY 1,088,818,555.81 in Q1 2023 from CNY 1,143,544,138.66 in Q1 2022, a decrease of 4.8%[40]. Research and Development - R&D investment totaled CNY 3,808.96 million, an increase of 136.89% year-on-year, representing 28.83% of operating revenue, up 17.42 percentage points[4]. - Research and development expenses reached CNY 38,089,598.74, significantly up from CNY 16,078,773.37, indicating a focus on innovation[49]. - The company launched new products including UniGel-65Q HC and STS0100 oligonucleotide synthesizer during the reporting period[9]. Shareholder Information - The total number of common shareholders at the end of the reporting period was 15,044[28]. - Major shareholder Shenzhen Nawei Technology Co., Ltd. holds 19.37% of the shares, totaling 78,096,992 shares[28]. - Equity attributable to shareholders of the listed company was CNY 159,270.72 million, reflecting a growth of 3.01% year-over-year[25]. Government Support and Other Income - The company received government subsidies amounting to CNY 385.86 million, which are closely related to its normal operations[25]. - The company reported a total of CNY 637.20 million in other income and expenses after tax impacts and minority interests[25]. - The total income from other sources was CNY 3,843,963.12, compared to CNY 2,383,320.11 previously, reflecting improved performance in ancillary revenue streams[49].